CYRX Cryoport, Inc.
Cryoport, Inc. provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and reproductive medicine markets worldwide. The company's Life Sciences Services segment provides temperature-controlled logistics and biostorage, bioservices and cryopreservation services within the life science industry. Its Life Sciences Products segment manufactures, and sells cryogenic freezers, cryogenic dewars, and related ancillary accessories within the life science industry through direct sales or a distribution network. The company's products include Cryoport Express Shippers; Cryoport Elite; Cryoport Express Cryogenic HV3 Shipping System; Smartpak Condition Monitoring System and Tec4Med, an IoT-based monitoring solutions; and Cryoport accessories. It also provides Cryoport BioStorage/Bioservices, such as Cryoport Systems Bioservices, including controlled temperature storage, kitting, labelling, fulfillment, sample management, drug return, and Qualified Person drug product release. In addition, the company offers IntegriCell services that comprise apheresis/leukapheresis collection, cryoshuttle transportation, cryo-process optimization, and cryopreservation services; Cryoport consulting services; MVE Fusion cryogenic system, a self-sustaining cryogenic freezer; and MVE Vario cryogenic system, a cryogenic freezer system. Further, it provides biological specimen cryopreservation storage and maintenance; archiving, monitoring, tracking, receipt, and delivery of samples; frozen biological specimens transportation; incoming and outgoing biological specimens management; and short-term logistics and engineering consulting services. The company was founded in 1999 and is based in Brentwood, Tennessee.…
Industry Peers
Integrated Freight & LogisticsKey Statistics
About Cryoport (NASDAQ: CYRX)
›
Cryoport (NASDAQ: CYRX) is listed on Nasdaq, where its shares trade in USD. It belongs to the Integrated Freight & Logistics industry, part of the Industrials sector, and reports about 684 employees.
The shares were at 19.05 USD on 20 November 2026, up 128.7% over 52 weeks. Its 52-week range is 7.610 USD to 21.78 USD: the price is 12.5% below the high and 150.3% above the low.
Its market capitalisation is 964.87M USD.
Cryoport reports return on equity of 15.6%, an operating margin of -14.4% and revenue up 13.5% year over year.
It holds more cash than debt, a net cash position of 161.56M USD. Its Piotroski F-score is 6 out of 9, an average reading of its financial health. 9 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 22.33 USD is 17.2% above the current price. The next earnings report is expected on 2 March 2027.